Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Israel
31%
COVID-19
26%
Invasive Aspergillosis
21%
Aspergillus Fumigatus
19%
Candida Albicans (C. albicans)
15%
Voriconazole
14%
Red Blood Cell Aggregation
14%
Virulence
12%
Pseudomonas Aeruginosa (P. aeruginosa)
12%
Candidemia
11%
Bacterial Infection
11%
Clinical Outcomes
11%
Candida Auris
10%
Healthcare Workers
10%
Posaconazole
10%
BNT162b2
9%
Invasive Fungal Disease
9%
Pseudomonas Aeruginosa Bacteraemia
9%
Bloodstream Infection
8%
Cat Scratch Disease
8%
BNT162b2 Vaccine
8%
Antifungal Therapy
8%
Invasive Candidiasis
8%
Angiogenesis
8%
Fumigatus
8%
Aurès
8%
Fluconazole
7%
Clinical Features
7%
Single Center
7%
Invasive Mold Infections
7%
Mucormycosis
7%
Red Blood Cells
7%
Chimeric Antigen Receptor T Cells (CAR-T)
7%
Echinocandins
7%
Fly Model
7%
Prospective Cohort Study
7%
Combination Therapy
7%
Risk Factors
7%
95% Confidence Interval
7%
Extended-spectrum-lactamase
7%
Israeli
7%
Monotherapy
7%
Immunocompromised Patients
6%
Sepsis
6%
Bacteremia
6%
C.albicans
6%
Candida
6%
Third Dose
6%
Mucorales
6%
Antifungal Drugs
5%
Immunology and Microbiology
Infection
100%
Infectious Disease
99%
Candida
22%
Aspergillosis
18%
COVID-19
18%
Aspergillus fumigatus
16%
Mould
15%
Candida Albicans
15%
Candida Auris
15%
Infectious Agent
14%
In Vitro
13%
Erythrocyte Aggregation
9%
Mortality Rate
8%
Immunosuppression
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Virus
7%
Angiogenesis
7%
Pseudomonas aeruginosa
7%
Candida Glabrata
7%
Cladistics
7%
Intravenous Immunoglobulin
7%
Enterobacteriaceae
7%
Regulatory T Cell
6%
Minimum Inhibitory Concentration
6%
Erythrocyte
6%
Antimicrobial Agent
6%
Susceptibility
6%
Fruit Fly
5%
Mucorales
5%
Fibrinogen
5%
Whole Genome Sequencing
5%
Medicine and Dentistry
Infection
32%
COVID-19
15%
Bloodstream Infection
12%
Mucormycosis
11%
Pseudomonas aeruginosa
9%
Diseases
9%
Health Care Personnel
9%
Invasive Aspergillosis
8%
Odds Ratio
7%
Retrospective Study
7%
Randomized Controlled Trial
6%
Cat-Scratch Disease
6%
Bacteriophage
6%
Human Immunodeficiency Virus
5%
Antibiotic Therapy
5%
Clinical Feature
5%